240 related articles for article (PubMed ID: 30587967)
1. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting.
Shobaki N; Sato Y; Harashima H
Int J Nanomedicine; 2018; 13():8395-8410. PubMed ID: 30587967
[TBL] [Abstract][Full Text] [Related]
2. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
3. A Multifunctional Envelope-Type Nano Device Containing a pH-Sensitive Cationic Lipid for Efficient Delivery of Short Interfering RNA to Hepatocytes In Vivo.
Sato Y; Harashima H; Kohara M
Methods Mol Biol; 2016; 1364():71-8. PubMed ID: 26472443
[TBL] [Abstract][Full Text] [Related]
4. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
Sakurai Y
Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells.
Sato Y; Hatakeyama H; Hyodo M; Harashima H
Mol Ther; 2016 Apr; 24(4):788-95. PubMed ID: 26678452
[TBL] [Abstract][Full Text] [Related]
6. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
[TBL] [Abstract][Full Text] [Related]
7. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution.
Nakamura T; Kawai M; Sato Y; Maeki M; Tokeshi M; Harashima H
Mol Pharm; 2020 Mar; 17(3):944-953. PubMed ID: 31990567
[TBL] [Abstract][Full Text] [Related]
9. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
11. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier.
Matsui H; Sato Y; Hatakeyama H; Akita H; Harashima H
Int J Pharm; 2015 Nov; 495(1):171-178. PubMed ID: 26355712
[TBL] [Abstract][Full Text] [Related]
12. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
[TBL] [Abstract][Full Text] [Related]
13. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
14. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration.
Carrasco MJ; Alishetty S; Alameh MG; Said H; Wright L; Paige M; Soliman O; Weissman D; Cleveland TE; Grishaev A; Buschmann MD
Commun Biol; 2021 Aug; 4(1):956. PubMed ID: 34381159
[TBL] [Abstract][Full Text] [Related]
15. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanoparticles for hepatic delivery of small interfering RNA.
Yu B; Hsu SH; Zhou C; Wang X; Terp MC; Wu Y; Teng L; Mao Y; Wang F; Xue W; Jacob ST; Ghoshal K; Lee RJ; Lee LJ
Biomaterials; 2012 Sep; 33(25):5924-34. PubMed ID: 22652024
[TBL] [Abstract][Full Text] [Related]
17. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
Kulkarni JA; Darjuan MM; Mercer JE; Chen S; van der Meel R; Thewalt JL; Tam YYC; Cullis PR
ACS Nano; 2018 May; 12(5):4787-4795. PubMed ID: 29614232
[TBL] [Abstract][Full Text] [Related]
18. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
19. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
20. pH-Dependent Phase Behavior and Stability of Cationic Lipid-mRNA Nanoparticles.
Larson NR; Hu G; Wei Y; Tuesca AD; Forrest ML; Middaugh CR
J Pharm Sci; 2022 Mar; 111(3):690-698. PubMed ID: 34774918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
